Deoxynucleoside Therapy for Thymidine Kinase 2–Deficient Myopathy
Objective Thymidine kinase 2, encoded by the nuclear gene TK2, is required for mitochondrial DNA maintenance. Autosomal recessive TK2 mutations cause depletion and multiple deletions of mtDNA that manifest predominantly as a myopathy usually beginning in childhood and progressing relentlessly. We investigated the safety and efficacy of deoxynucleoside monophosphate and deoxynucleoside therapies. Methods We administered deoxynucleoside monophosphates and deoxynucleoside to 16 TK2‐deficient patients under a compassionate use program. Results In 5 patients with early onset and severe disease, survival and motor functions were better than historically untreated patients. In 11 childhood and adult onset patients, clinical measures stabilized or improved. Three of 8 patients who were nonambulatory at baseline gained the ability to walk on therapy; 4 of 5 patients who required enteric nutrition were able to discontinue feeding tube use; and 1 of 9 patients who required mechanical ventilation became able to breathe independently. In motor functional scales, improvements were observed in the 6‐minute walk test performance in 7 of 8 subjects, Egen Klassifikation in 2 of 3, and North Star Ambulatory Assessment in all 5 tested. Baseline elevated serum growth differentiation factor 15 levels decreased with treatment in all 7 patients tested. A side effect observed in 8 of the 16 patients was dose‐dependent diarrhea, which did not require withdrawal of treatment. Among 12 other TK2 patients treated with deoxynucleoside, 2 adults developed elevated liver enzymes that normalized following discontinuation of therapy. Interpretation This open‐label study indicates favorable side effect profiles and clinical efficacy of deoxynucleoside monophosphate and deoxynucleoside therapies for TK2 deficiency. ANN NEUROL 2019;86:293–303.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:86 |
|---|---|
| Enthalten in: |
Annals of Neurology - 86(2019), 2, Seite 293-303 |
| Beteiligte Personen: |
Domínguez‐González, Cristina [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2019 American Neurological Association |
|---|
| Umfang: |
11 |
|---|
| doi: |
10.1002/ana.25506 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY001697587 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY001697587 | ||
| 003 | DE-627 | ||
| 005 | 20230307105941.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230210s2019 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/ana.25506 |2 doi | |
| 028 | 5 | 2 | |a ANA_ANA25506.xml |
| 035 | |a (DE-627)WLY001697587 | ||
| 035 | |a (WILEY)ANA25506 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.90 |2 bkl | ||
| 084 | |a 44.67 |2 bkl | ||
| 100 | 1 | |a Domínguez‐González, Cristina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Deoxynucleoside Therapy for Thymidine Kinase 2–Deficient Myopathy |
| 264 | 1 | |c 2019 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2019 American Neurological Association | ||
| 520 | |a Objective Thymidine kinase 2, encoded by the nuclear gene TK2, is required for mitochondrial DNA maintenance. Autosomal recessive TK2 mutations cause depletion and multiple deletions of mtDNA that manifest predominantly as a myopathy usually beginning in childhood and progressing relentlessly. We investigated the safety and efficacy of deoxynucleoside monophosphate and deoxynucleoside therapies. Methods We administered deoxynucleoside monophosphates and deoxynucleoside to 16 TK2‐deficient patients under a compassionate use program. Results In 5 patients with early onset and severe disease, survival and motor functions were better than historically untreated patients. In 11 childhood and adult onset patients, clinical measures stabilized or improved. Three of 8 patients who were nonambulatory at baseline gained the ability to walk on therapy; 4 of 5 patients who required enteric nutrition were able to discontinue feeding tube use; and 1 of 9 patients who required mechanical ventilation became able to breathe independently. In motor functional scales, improvements were observed in the 6‐minute walk test performance in 7 of 8 subjects, Egen Klassifikation in 2 of 3, and North Star Ambulatory Assessment in all 5 tested. Baseline elevated serum growth differentiation factor 15 levels decreased with treatment in all 7 patients tested. A side effect observed in 8 of the 16 patients was dose‐dependent diarrhea, which did not require withdrawal of treatment. Among 12 other TK2 patients treated with deoxynucleoside, 2 adults developed elevated liver enzymes that normalized following discontinuation of therapy. Interpretation This open‐label study indicates favorable side effect profiles and clinical efficacy of deoxynucleoside monophosphate and deoxynucleoside therapies for TK2 deficiency. ANN NEUROL 2019;86:293–303 | ||
| 700 | 1 | |a Madruga‐Garrido, Marcos |4 aut | |
| 700 | 1 | |a Mavillard, Fabiola |4 aut | |
| 700 | 1 | |a Garone, Caterina |4 aut | |
| 700 | 1 | |a Aguirre‐Rodríguez, Francisco Javier |4 aut | |
| 700 | 1 | |a Donati, M. Alice |4 aut | |
| 700 | 1 | |a Kleinsteuber, Karin |4 aut | |
| 700 | 1 | |a Martí, Itxaso |4 aut | |
| 700 | 1 | |a Martín‐Hernández, Elena |4 aut | |
| 700 | 1 | |a Morealejo‐Aycinena, Juan P. |4 aut | |
| 700 | 1 | |a Munell, Francina |4 aut | |
| 700 | 1 | |a Nascimento, Andrés |4 aut | |
| 700 | 1 | |a Kalko, Susana G. |4 aut | |
| 700 | 1 | |a Sardina, M. Dolores |4 aut | |
| 700 | 1 | |a Álvarez del Vayo, Concepcion |4 aut | |
| 700 | 1 | |a Serrano, Olga |4 aut | |
| 700 | 1 | |a Long, Yuelin |4 aut | |
| 700 | 1 | |a Tu, Yuqi |4 aut | |
| 700 | 1 | |a Levin, Bruce |4 aut | |
| 700 | 1 | |a Thompson, John L. P. |4 aut | |
| 700 | 1 | |a Engelstad, Kristen |4 aut | |
| 700 | 1 | |a Uddin, Jasim |4 aut | |
| 700 | 1 | |a Torres‐Torronteras, Javier |4 aut | |
| 700 | 1 | |a Jimenez‐Mallebrera, Cecilia |4 aut | |
| 700 | 1 | |a Martí, Ramon |4 aut | |
| 700 | 1 | |a Paradas, Carmen |4 aut | |
| 700 | 1 | |a Hirano, Michio |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of Neurology |g 86(2019), 2, Seite 293-303 |w (DE-627)WLY001695479 |x 15318249 |7 nnns |
| 773 | 1 | 8 | |g volume:86 |g year:2019 |g number:2 |g pages:293-303 |g extent:11 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.90 |q ASE |
| 936 | b | k | |a 44.67 |q ASE |
| 951 | |a AR | ||
| 952 | |d 86 |j 2019 |e 2 |h 293-303 |g 11 | ||